Management of anaemia and iron deficiency in patients with cancer: ESMO Clinical Practice Guidelines†

Anaemia and iron deficiency (ID) are frequent complications in patients with solid tumours or haematological malignancies, particularly in patients treated with chemotherapeutic agents [1–3]. Frequently, anaemia is associated with fatigue, impaired physical function and reduced quality of life (QoL) [4–7]. Consequences of anaemia may include impaired response to cancer treatment and reduced overall survival (OS), even though a causal direct relationship has not yet been established [8, 9].

from Cancer via ola Kala on Inoreader http://ift.tt/2om9mbt
via IFTTT